Imatinib mesylate for the treatment of hypereosinophilic syndromes

Current Opinion in Investigational Drugs

Volumn 7, Issue 11, 2006, Pages 980-984

  Antoniu, Sabina A ^a  

^a Clinic of Pulmonary Disease   (Romania)

Author keywords

Hypereosinophilic syndrome; Imatinib mesylate; Tyrosine kinase inhibition

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CORTICOSTEROID; CYTARABINE; CYTOTOXIC AGENT; DASATINIB; HYDROXYUREA; IMATINIB; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

CARDIOVASCULAR SYMPTOM; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE FUSION; GENE IDENTIFICATION; GENETIC CODE; GENETIC RISK; HUMAN; HYPEREOSINOPHILIC SYNDROME; LONG TERM CARE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MORTALITY; MYELOPROLIFERATIVE DISORDER; MYOPATHY; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PATHOGENESIS; PROGNOSIS; REMISSION; REVIEW; SHORT COURSE THERAPY; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT DURATION; ULCER;

EID: 33751023463     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Pardanani A, Tefferi A: Imatinib targets other than Bcr/Abl and their clinical relevance in myeloid disorders. Blood (2004) 104(7):1931-1939.
2. Kilon Ad: Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Am Soc Hematol Educ Program (2005):209-214.
3. Prevalence of rare diseases: A bibliographic survey June 2006. Ophanet, Paris, France (2006). http//www.orpha.net/orphacom/cahiers/docs/GB/ Prevalence_of_rare_diseases.pdf
4. Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndromes: Analysis of fourteen cases with review of the literature. Medicine(Baltimore) (1975) 54(1):1-27.
5. Idiopathic hypereosinophilic syndrome: Orphamet, Paris, France (2004). http://www.orpha.net/data/patho/GB/uk-IdiopHypereosinophSyndr.pdf
6. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hyperoosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood (2003) 101(12):4660-4666.
7. Bank I, Amariglio N, Reshef A, Harden I, Confino Y, Trau H, Shtrasburg S, Langevitz P, Monselise Y, Shalit M, Rechavi G: The hyperoosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma (2001) 42(1-2):123-133.
8. Roufosse F, Schandene L, Sibille C, Willard-Gallo K, Kennes B, Efira A, Goldman M, Cogan E: Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol (2000) 109(3):540-548.
9. Brugnoni D, Airo P, Rossi G, Bettinardi A, Simon HU, Garza L, Tosoni C, Cattanso R, Blaser K, Tucci A: A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood (1996) 87(4):1416-1422.
10. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE: The FIPIL1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood (2004) 103(8):2879-2891.
11. Pitini V, Arrigo C, Azzarello D, La Gattuta G, Amata C, Righi M, Coglitore S: Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood (2003) 102(9):3456-3457.
12. Sakamoto K, Erdreich-Epstein A, Declerck Y, Coates T: Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol (1992) 14(4):348-351.
13. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M: 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer (2005) 104(3):541-546.
14. Schandene L, Roufosse F, de Lavareille A, Stordeur P, Efira A, Kennes B, Cogan E, Goldman M: Interferon α prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood (2000) 98(13):4285-4292.
15. Schandene L, Del Prete GF, Cogan E, Stordeur P, Crusiaux A, Kennes B, Romagnani S, Goldman M: Recombinant interferon-α selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest (1996) 97(2):309-315.
16. Butterfield JH: Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol (2005) 114(1):26-40.
17. Aldebert D, Lamkhioued B, Desaint C, Gounni AS, Goldman M, Capron A, Prin L, Capron M: Eosinophils express a functional receptor for interferon α: Inhibitory role of interferon α on the release of mediators. Blood (1996) 87(8):2354-2380.
18. Schandene L, Cogan E, Crusiaux A, Goldman M: Interferon-α upregulates both interleukin-10 and interferon-γ production by human CD4+ T cells. Blood (1997) 89(3):1110-1111.
19. Schoffski P, Ganser A, Pascheberg U, Busche G, Gaede B, Hertenstein B: Complete haematological and cytogenetic response to interferon α-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol (2000) 79(2):95-98.
20. Ceretelli S, Capochiani E, Petrini M: Interferon-α in the idiopathic hypereosinophilic syndrome: Consideration of five cases. Ann Hematol (1998) 77(4):161-164.
21. Butterfield JH, Gleich G: Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med (1994) 121(9):648-653.
22. Murphy PT, Fennelly DF, Stuart M, O'Donnell JR: α-interferon in a case of hypereosinophilic syndrome. Br J Haematol (1990) 75(4):619-620.
23. Demiroglu H, Dundar S: Combination of interferon-α and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br J Haematol (1997) 97(4):928-930.
24. Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M et al: Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol (2002) 119(1):131-134.
25. Cooper MA, Akard LP, Thompson JM, Dugan MJ, Jansen J: Hypereosinophilic syndrome: Long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant. Am J Hematol (2005) 78(1):33-36.
26. Jones RL, Judson IR: The development and application of imatinib. Expert Opin Drug Saf (2005) 4(2):183-191.
27. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 348(13):1201-1214.
28. Schwartz RS: The hypereosinophilic syndrome and the biology of cancer. N Engl J Med (2003) 348(13):1199-1200.
29. Gleevec (imatinib mesylate) Prescribing information: Novartis Pharmaceuticals Corp, East Hanover, NJ, USA (2003). http://www.fda.gov/ cder/foi/label/2003/021588s002lbl.pdf
30. Frickhofen N, Marker-Hermann E, Reiter A, Walz C, Jung B, Bauer H, Hochhaus A: Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol (2004) 83(7):477-480.
31. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB: Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood (2004) 103(2):473-478.
32. Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M: Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-α positive idiopathic hypereosinophilic syndrome. Haematologica (2004) 89(2):236-237.
33. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood (2003) 101(9):3391-3397.
34. Rose C, Dupire S, Roche-Lestienne C, Grardel N, Bourgeois E, Cambier N, Preudhomme C: Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia (2004) 18(2):354-355.
35. Vandenberghe P, Wodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M et al: Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia (2004) 18(4):734-742.
36. Elliott MA, Pardanani A, Li CY, Tefferi A: Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilla-associated mastocytosis. Leukemia (2004) 18(5):1027-1029.
37. Schaller JL, Burkland GA: Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed (2001) 3(5):9.
38. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H: Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res (2002) 26(9):881-884.
39. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Werda W, Rios MB, Letvak L, Kaled ES, Kantarjian H: Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood (2003) 101(12):4714-4716.
40. Gleich GJ, Lederman KM, Pardanani A, Teffed A, Butterfield JH: Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet (2002) 359(9317):1577-1578.
41. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, Blasiak J, Skorski T: Bcr/Abl kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood (2006) 108(1):319-327.
42. Villuendas R, Steegmann JL, Pollan M, Tracey L, Granda A, Fernandez-Ruiz E, Casado LF, Martinez J, Martinez P, Lombardia L, Villalon L et al: Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia (2006) 20(6):1047-1054.
43. Tokarski JS, Newitt JA, Chang CY, Chang JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzilerri R, Lombardo LJ, Xie D et al: The structure of dasatinib (BMS-354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants. Cancer Res (2006) 66(11):5790-5797.
44. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 354(24):2542-2551.
45. Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA et al: Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol (2004) 113(1):115-119.
46. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J: Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med (2003) 349(24):2334-2339.